Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rhythm Pharmaceuticals (RYTM) Raw Materials (2022 - 2025)

Rhythm Pharmaceuticals (RYTM) has disclosed Raw Materials for 4 consecutive years, with $7.2 million as the latest value for Q3 2025.

  • Quarterly Raw Materials rose 43.01% to $7.2 million in Q3 2025 from the year-ago period, while the trailing twelve-month figure was $7.2 million through Sep 2025, up 43.01% year-over-year, with the annual reading at $6.8 million for FY2024, 46.51% up from the prior year.
  • Raw Materials for Q3 2025 was $7.2 million at Rhythm Pharmaceuticals, up from $4.5 million in the prior quarter.
  • The five-year high for Raw Materials was $7.2 million in Q3 2025, with the low at $2.3 million in Q2 2023.
  • Average Raw Materials over 4 years is $4.4 million, with a median of $4.6 million recorded in 2023.
  • Peak annual rise in Raw Materials hit 82.2% in 2024, while the deepest fall reached 31.3% in 2024.
  • Over 4 years, Raw Materials stood at $2.7 million in 2022, then skyrocketed by 69.91% to $4.6 million in 2023, then soared by 46.51% to $6.8 million in 2024, then grew by 5.95% to $7.2 million in 2025.
  • According to Business Quant data, Raw Materials over the past three periods came in at $7.2 million, $4.5 million, and $5.0 million for Q3 2025, Q2 2025, and Q1 2025 respectively.